VJHemOnc is committed to improving our service to you

EHA 2020 | Significance of MRD in CLL

VJHemOnc is committed to improving our service to you

Tanya Siddiqi

Tanya Siddiqi, MD, of City of Hope, Duarte, CA, explores the use of minimal residual disease (MRD) testing in the clinic for chronic lymphocytic leukemia (CLL) patients, and its use in determining the endpoint for treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter